MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
2.105
-0.125
-5.61%
Opening 15:44 06/30 EDT
OPEN
2.200
PREV CLOSE
2.230
HIGH
2.290
LOW
2.100
VOLUME
4.47M
TURNOVER
--
52 WEEK HIGH
2.855
52 WEEK LOW
0.5300
MARKET CAP
365.39M
P/E (TTM)
-1.7996
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)
TipRanks · 9h ago
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Palisade Bio (PALI)
TipRanks · 13h ago
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
TipRanks · 1d ago
Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial
Dow Jones · 1d ago
Palisade Bio receives FDA clearance to start ulcerative colitis study
TipRanks · 1d ago
Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative Colitis
Benzinga · 1d ago
Palisade Bio wins FDA IND clearance for PALI-2108 ulcerative colitis trial
PUBT · 1d ago
PALISADE BIO - EXPECTS TO SUBMIT IND FOR ASCENTRA-CD IN CROHN'S DISEASE IN H2 2026
Reuters · 1d ago
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.